Product availability varies by country. Consult your bioMérieux representative.

^*Investigational use only. Currently under FDA review. Not available for sale.

^**This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

^ǂDesigned to run on the BIOFIRE^® FILMARRAY^® 2.0 EZ configuration system in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

^ǂǂIntended to be run in a CLIA-moderate setting on the BIOFIRE^® FILMARRAY^® TORCH and BIOFIRE^® FILMARRAY^® 2.0 Systems.

©2022 bioMérieux, Inc. • BIOMÉRIEUX, the BIOMÉRIEUX logo, PIONEERING DIAGNOSTICS, BIOFIRE, and FILMARRAY are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies • Patents • 515 Colorow Drive, Salt Lake City, UT 84108 • Tel: (800) 634-7656

bioMérieux S.A. • 69280 Marcy l’Etoile • France •  www.biomerieux-usa.com

Privacy Policy

Who We Are - bioMérieux

Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place.

#PioneeringDiagnostics

Visit our booth and learn more about onsite molecular infectious disease diagnostics from bioMérieux.

BIOFIRE^® Respiratory 2.1-EZ (RP2.1-EZ) Panel (EUA)**:

This syndromic panel identifies 19 respiratory targets—including SARS-CoV-2—in one fast and easy test. Intended for use with patients suspected of COVID-19, the BIOFIRE RP2.1-EZ Panel (EUA) enables fast, comprehensive in-clinic testing.^ǂ Authorized for use under an FDA Emergency Use Authorization.

For use with the BIOFIRE^® FILMARRAY^® 2.0 EZ configuration.

Want to learn more?

Fill out the form below to have a representative reach out to you.

By checking the box, you have read and agree to the Privacy Policy and agree to receive emails from bioMérieux on new products, newsletters, surveys or upcoming events. You can unsubscribe at any time.

BIOFIRE^® Joint Infection Panel:

Test for a comprehensive grouping of gram-positive and gram-negative bacteria, yeast, and antimicrobial resistance genes commonly associated with joint infections. It takes just one test, one 0.2 mL sample of synovial fluid, and about an hour to get results on 39 clinically relevant targets.^ǂǂ 
US FDA cleared.

For use in a CLIA-moderate setting with the BIOFIRE^® FILMARRAY^® TORCH or the BIOFIRE FILMARRAY 2.0. 

Product Theater

Leveraging BioFire BCID2 for Diagnostic and Antimicrobial Stewardship  

*Investigational use only. Currently under FDA review. Not available for sale.

Date: Thursday, September 22, 2022
Where: Theater 6

BIOFIRE^® FILMARRAY^® Gastrointesintal (GI) Panel:

Test for 22 of the most common GI pathogens including bacteria, viruses, and parasites—all in about an hour, directly on-site.^ǂǂ 
US FDA cleared.

For use in a CLIA-moderate setting with the BIOFIRE^® FILMARRAY^® TORCH or the BIOFIRE FILMARRAY 2.0. 

12:15 - 1:00 pm ET

BIOFIRE^® Syndromic Trends (Trend):

This software feature provides pathogen trends for your lab as well as regional and national pathogen trends. Get automatic weekly email reports and explore your data using BIOFIRE Trend’s dashboard.

Gastrointestinal pathogen trends from BIOFIRE Trend.

THIS

CHANGES

EVERYTHING

Visit booth #1303 to see the faster, smaller, and smarter BIOFIRE^® SPOTFIRE^® System.*

BIOFIRE is now bioMérieux.